RemeGen Co., Ltd. announced that its phase 3 clinical trial (Study ID: RC48-C016) has reached its two primary endpoints of progression-free survival (PFS) and overall survival (OS).
At 2025 ASCO GU, Prof. Xinan Sheng disclosed phase II trial data of DV + Toripalimab for HER2 - expressing MIBC, showing high pCR and manageable safety.
Seagen and a Chinese company, RemeGen, have signed an exclusive global licencing agreement to develop and market a new HER2-targeted antibody-drug conjugate (ADC), disitamab vedotin.